

## Methodological note with regards to Transfers of Value (ToV) to Healthcare Professionals (HCP), Healthcare Organizations (HCO) and Patient Organizations, during the calendar year 2019.

This methodological note applies to following Mylan legal entities registered in Finland:

Mylan Finland Oy and Meda Oy – hereinafter referred to as “Mylan”.

### Introduction and scope

The basis for publishing the Disclosure for ToV is in Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 and updated January 2016, as defined by the code as a rule of membership of the trade association. This Disclosure concerns the calendar year 2019.

ToV can be provided by Mylan to HCPs, HCOs and Patient organizations either as payment for services (use of HCPs or HCOs as scientific consultants) or payment for support memberships of non-profit Patient organizations. They can also be provided indirectly by third parties in the form of accommodation, travel or registration fee for HCPs to attend scientific educational events. The consulting payments include the collaboration on Patient support programs.

Subsistence of Mylan’s own personnel does not fall under the scope of Finnish Generics Medicines Association (Rinnakkaislääketeollisuus ry) requirements for Disclosure and therefore it has been left out of the scope.

### Data collection

Payments made to HCPs, HCOs and Patient organizations during calendar year 2019 were collected from Mylan’s internal financial systems and internal tracking processes. Names and addresses were collected as per the location of workplace and matched with IMS OneKey database information.

Consent to disclose ToV provided to HCPs had been requested from the HCPs as a part of contract work, with the option to refuse the publication of HCP name. However, due to the COVID-19 pandemic business continuity situation, Mylan has disclosed the monetary benefits of the healthcare professional concerned as an aggregate value, regardless of whether HCPs have given their consent to publish their names or not, as per the guidance which came out from Medicines for Europe in May 2020.

### Date used for data provision

For direct payments, the date when transaction was made, is the date provided for collection of ToV.

For indirect payments, for instance conferences, where travel, accommodation and hospitality were provided, the date of conference, meeting or other event, is captured as the date of ToV in Mylan reporting tool.

## Treatment of value added tax (VAT)

Mylan reports ToV as net value, without VAT.

## Cross-border payments

Mylan operates internationally and therefore cross-border payments need to be considered in ToV payments reporting. Mylan's data reporting tool allows cross-border payments to be reported to the country of HCP's permanent address.

## Education of HCPs through HCOs

When Mylan provides HCPs with ToV through providing scientific education through HCOs or teaching institutions, the ToV is disclosed in the HCP support aggregate and not the HCO to avoid duplicate reporting.

## Multi-year contracts

There were no multi-year contracts to disclose in year 2019.

## Support Memberships

Mylan provides support for non-profit Healthcare Organizations (HCO) in order to support science and education for genuine philanthropic and charitable purposes. Contributions are provided to recognized charities, civic organisations, not for-profit institutions which have charitable or philanthropic objectives as their main purpose, and/or community and charitable initiatives, but never to for-profit entities. Contributions are given for the purpose of supporting scientific research, medical education, patient education, patient access to healthcare, or the overall development of healthcare systems. This support is reported under ToV for HCO documentation.